
Gene therapy startup GEMMABio, led by industry trailblazer Jim Wilson, has secured $34 million in seed funding to transform treatment options for rare diseases. Wilson, formerly of the University of Pennsylvania, founded GEMMABio and Franklin Biolabs earlier this year. His contributions to gene therapy, particularly in gene delivery techniques, have significantly advanced the field.
This latest funding round, backed by Double Point Ventures, Bioluminescence Ventures, Earlybird Venture Capital, and Savanne Life Sciences, follows a $100 million boost in October. GEMMABio plans to channel these funds into producing and testing six gene therapies in Brazil, targeting debilitating conditions like GM1 gangliosidosis, a severe neurological disorder.
A key partnership with Fiocruz, a major supplier to Brazil’s Ministry of Health, underscores GEMMABio’s commitment to accessibility. By leveraging Brazil’s public healthcare system, Sistema Único de Saúde (SUS), GEMMABio aims to make life-changing therapies available to underserved populations.
Gene therapy has recently seen unprecedented progress, with 2023 setting a record for FDA approvals. However, challenges persist, particularly in scaling and manufacturing these advanced treatments. Despite their curative potential, gene therapies are among the most expensive medical interventions due to intricate production processes and limited patient pools.
An example is Orchard Therapeutics’ Lenmeldy, a $4.25 million therapy for metachromatic leukodystrophy (MLD), projected to generate $154 million in sales by 2030. These costs highlight the need for innovative solutions to make such treatments broadly accessible.
Jim Wilson emphasized the urgency of the mission, stating, “This funding arrives at a critical juncture, enabling us to accelerate the development of affordable therapies for patients who need them most.”
With its innovative approach and strong financial backing, GEMMABio is set to redefine the landscape of gene therapy, bringing hope to patients worldwide.

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE